Anup Kasi Loknath Kumar

20PUBLICATIONS
138CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 02, 2025
The XPO1 Inhibitor Eltanexor Modulates the Wnt/β-Catenin Signaling Pathway to Reduce Colorectal Cancer Tumorigenesis.

Andrew E Evans, Sahida Afroz, Alexa Magstadt

|May 31, 2025
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.

Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana

|Mar 06, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.

Lakshmi Rajdev, Gentry G King, Christopher H Lieu

|Feb 07, 2025
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.

Qamar J Khan, Colleen Bohnenkamp, Taylor E Monson

|Jan 17, 2025
Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.

Bach Ardalan, Aaron Ciner, Yasmine Baca

|Oct 30, 2024
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.

Daniel H Ahn, Maya Ridinger, Timothy L Cannon

Pageof 4

Frequent Collaborators

2 joint publications

Eric Van Cutsem

2 joint publications

Philip A Philip

2 joint publications

Joaquina Celebre Baranda

2 joint publications

Raed Moh'd Taiseer Al-Rajabi